Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
MERLINTRADER · BIOTECH RADAR
Biotech Radar — October 26–27, 2026: $ARTV, $BEAM, $MRK, $PFE
Artiva ends AlloNK; Beam presents initial BEAM-301 findings at ESGCT after its October 13 preview; Merck presents survival findings in endometrial cancer; Pfizer combines an FDA approval with a new Phase 3 success. The October 26–27 Radar also covers other trials, regulatory developments, deals, earnings and upcoming sector events.
The four stocks: daily charts
Four stories in focus
$ARTV
Artiva ends AlloNK: clinical risk becomes a corporate reset
AlloNK halted · planned 94% workforce reduction
$BEAM
BEAM-301: two patients stop starch supplementation, with safety in focus
GSDIa · 2 of 3 patients at 40 mg reach 15 hours of fasting
$MRK
Merck: sac-TMT extends survival, with a separate Keytruda advance
TroFuse-005 · median OS 19.0 versus 12.1 months
$PFE
Pfizer: an earlier TALZENNA approval and a Phase 3 win for ELREXFIO
FDA approval on Oct. 26 · MagnetisMM-32 topline on Oct. 27
01 · Artiva ends AlloNK: clinical risk becomes a corporate reset · $ARTV
2026-10-27
Artiva is ending AlloNK development, including its planned Phase 3, after reassessing benefit, response durability and safety. One fatal event was considered likely related to fludarabine neurotoxicity; the second was judged unrelated to treatment components, with its cause undetermined. The planned workforce reduction is approximately 94%. Cash, equivalents and investments were about $319.1 million at September 30, a preliminary, unaudited figure.
The shareholder question changes: close-out costs, liabilities and the destination of remaining resources now matter alongside clinical results. Reported cash is not a distributable amount. Strategic alternatives include corporate transactions, asset sales and potentially liquidation, with no guaranteed outcome.
What comes next: orderly trial close-out and strategic review; workforce reductions expected by the first quarter of 2027. Key risk: total costs cannot yet be reasonably estimated and strategic outcomes remain uncertain.
02 · BEAM-301: two patients stop starch supplementation, with safety in focus · $BEAM
2026-10-27
By August 17, six patients had received BEAM-301 in the open-label Phase 1/2 study for R83C-associated GSDIa. In the 40 mg cohort, two of three reached 15 hours of controlled fasting and stopped starch supplementation. Four of the six patients overall experienced serious adverse events considered treatment-related, including three Grade 3 infusion reactions. Premedication and infusion rates have been modified.
On October 27, Beam presents at ESGCT findings previewed on October 13. Fasting control is a tangible outcome in a disease requiring intensive dietary management. The very small sample makes each patient’s course consequential and requires efficacy and safety to be assessed together.
What comes next: enrollment in the 60 mg cohort and planned FDA discussions. Key risk: durability, reproducibility and tolerability in a broader population.
03 · Merck: sac-TMT extends survival, with a separate Keytruda advance · $MRK
2026-10-26
TroFuse-005, a Phase 3 study in 776 patients with endometrial cancer previously treated with platinum and anti-PD-(L)1 therapy, showed median overall survival of 19.0 versus 12.1 months with chemotherapy: HR 0.68. PFS was 7.2 versus 3.9 months, HR 0.59. Grade 3 or higher treatment-related events occurred in 54.4% versus 41.4%. The BLA is under Priority Review, with an FDA target date of June 15, 2027.
In the separate first-line dMMR KEYNOTE-C93 study, Keytruda monotherapy produced PFS of 38.2 versus 8.4 months; an overall-survival advantage was not statistically established. The trials address different populations and treatment settings.
The useful read-through is a broader range of options along the treatment pathway. For sac-TMT, a survival benefit carries more weight than response alone, but must be weighed against toxicity and the pending regulatory review. The full presentation adds detail to previously announced positive results.
What comes next: BLA review and a fuller assessment of benefit and risk.
04 · Pfizer: an earlier TALZENNA approval and a Phase 3 win for ELREXFIO · $PFE
2026-10-27
On October 26, the FDA approved talazoparib with enzalutamide for metastatic prostate cancer with HRR mutations that is naïve or sensitive to androgen-pathway modulation. This is an actual indication expansion for TALZENNA plus XTANDI.
On October 27, MagnetisMM-32 met its primary PFS endpoint for ELREXFIO in relapsed/refractory myeloma after at least one prior line including anti-CD38 therapy and lenalidomide. Estimated 18-month PFS was 68%; median PFS was not reached and OS remains immature. Grade 3 or higher infections occurred in 27.5% versus 18.1% with comparator regimens.
For TALZENNA, attention turns to adoption in the newly authorized population. For ELREXFIO, Phase 3 strengthens the evidence package, while potential earlier-line use depends on subsequent regulatory steps. An approval and positive trial results remain different milestones.
What comes next: full MagnetisMM-32 details, OS maturation and regulatory initiatives. Key risk: infection management and positioning in an increasingly competitive myeloma market.
Other developments to read first
BioNTech/DualityBio: a positive Phase 3 endpoint with limited benefit · $BNTX
2026-10-26 — DYNASTY-Breast02 met its PFS endpoint, but the companies described the improvement as modest. Trastuzumab pamirtecan was associated with more interstitial lung disease, including some severe and fatal cases; OS is immature. The companies consider potential benefit limited in the studied HR+/HER2-low population and will discuss next steps.
BMY/SystImmune: iza-bren PFS of 11.1 versus 5.7 months · $BMY
2026-10-26 — In Phase 3 PANKU-Lung01 after an EGFR-TKI in EGFR-mutated lung cancer, iza-bren reduced progression or death risk: HR 0.40. The trial was conducted in China; overall survival remains immature. The result supports the EGFR×HER3 bispecific ADC program, with further evidence and regulatory steps ahead.
AbbVie submits the etentamig BLA in myeloma · $ABBV
2026-10-27 — The filing is supported by Phase 3 CERVINO: objective response 74.0% versus 45.7% and a 60% reduction in PFS risk versus investigator-selected available therapies. Monthly administration is a program feature; Grade 3/4 infections occurred in 27.7% versus 19.2%. BLA submission is a filing milestone, with approval still pending.
Vanda: positive Phase 3 results against GLP-1-associated vomiting · $VNDA
2026-10-27 — In Study 3601, vomiting occurred in 43.0% with tradipitant versus 58.5% with placebo, p=0.006. Participants received a single 1 mg semaglutide dose without gradual titration, making real-world transferability a relevant question. Vanda plans FDA discussions and an sNDA for this indication.
Release / document 1 · Hub $VNDA
Oruka: EVERLAST-B reinforces the psoriasis signal · $ORKA
2026-10-26 — At Week 16, PASI100 was 61% and PASI90 86% with 600 mg, versus 0% for both with placebo. The Phase 2b enrolled 187 patients, including 46 in the high-dose group. Initial doses were given at Weeks 0 and 4. Durability and annual maintenance remain under evaluation; Phase 3 is planned for the first half of 2027.
Release / document 1 · Hub $ORKA
HUTCHMED: the oral SANOVO combination in first-line lung cancer · $HCM
2026-10-26 — Savolitinib plus osimertinib produced median PFS of 24.9 versus 13.8 months with osimertinib alone, HR 0.56, in EGFR-mutated tumors with MET overexpression. This Phase 3 trial was conducted in China and concerns a specific biomarker-selected population. Broader use of the combination requires the relevant market-specific regulatory steps.
Corcept: BELLA adds bevacizumab to the combination · $CORT
2026-10-26 — In BELLA Part A, 95 patients with platinum-resistant ovarian cancer received relacorilant, nab-paclitaxel and bevacizumab: median PFS was 7.2 months and response 59%. This is an open-label, single-arm study; comparisons with ROSELLA are cross-trial comparisons. The triplet remains investigational.
Release / document 1 · Hub $CORT
Mirum: PROGRESS in children younger than 12 · $MIRM
2026-10-26 — PROGRESS Cohort 2, in children aged 6 to under 12 with FOP, showed reduced heterotopic-ossification lesion volume with zilurgisertib versus placebo at 24 weeks. No treated patient developed new lesions. Mirum plans an sNDA in the first half of 2027; the existing approval covers patients aged 12 and older.
Longeveron: favorable MACE findings, with the primary endpoint missed · $LGVN
2026-10-26 — ELPIS II, a Phase 2b in 40 infants with HLHS, missed its primary 12-month ventricular-function endpoint. Further analysis of the prespecified MACE secondary endpoint showed eight events with control and one with laromestrocel, p=0.043. The company plans to request an FDA meeting; the secondary result does not resolve the missed primary endpoint.
Release / document 1 · Hub $LGVN
Aclaris: early proof of concept for ATI-052 · $ACRS
2026-10-27 — Two randomized Phase 1b trials enrolled 14 patients with atopic dermatitis and 16 with asthma. In the dermatitis per-protocol analysis, after four exclusions, EASI changed by −58% with ATI-052 versus −13% with placebo. Samples are small; the company is prioritizing initial Phase 2b development in eosinophilic esophagitis.
Innate/AstraZeneca: PACIFIC-9 moves to the first half of 2027 · $IPHA
2026-10-27 — The expected Phase 3 readout moves from the second half of 2026 to the first half of 2027 because the trial is event-driven. PACIFIC-9 evaluates durvalumab with monalizumab or oleclumab in unresectable Stage III lung cancer after chemoradiation. The timing change does not report a negative outcome.
Teva acquires BioXcel assets, including BXCL501 · $TEVA
2026-10-27 — The asset acquisition closed for $57.5 million upfront and up to $67.5 million contingent consideration. It includes worldwide BXCL501 rights; at-home use for agitation associated with schizophrenia and bipolar disorder remains under FDA review. Acquiring the assets is separate from acquiring BioXcel as a company.
Cumberland: plans an ifetroban NDA · $CPIX
2026-10-26 — The company plans to use FIGHT DMD and natural-history database comparisons for Duchenne cardiomyopathy, with rolling review granted. The release also states that FDA had suggested a Phase 3 and raised endpoint, comparator and analysis questions. Planned submission leaves evidence sufficiency as an open regulatory risk.
Arrowhead: REDEMPLO access in England and Wales · $ARWR
2026-10-27 — The announcement reports U.K. authorization and a NICE funding recommendation for adults with genetically confirmed FCS inadequately controlled by diet and conventional treatment. MHRA labeling and NICE access conditions have distinct scopes; a commercial arrangement accompanies health-service access.
Release / document 1 · Hub $ARWR
Phathom: an FDA docket and VOQUEZNA litigation · $PHAT
2026-10-26 — FDA opened a public docket on regulatory questions raised by BDR in litigation concerning an ANDA referencing VOQUEZNA. Phathom plans to intervene. This concerns exclusivity and the generic regulatory pathway, without announcing approval of a competitor.
Oncology: clinical findings and early signals
Iovance: four responses among eight patients with sarcoma · $IOVA
2026-10-26 — In the lifileucel pilot, four of eight evaluable patients with UPS or DDLPS had confirmed partial responses, all ongoing at September 9. The small sample, investigator assessment and lack of a control limit interpretation. Sarcoma expansion is separate from existing authorized indications.
Release / document 1 · Hub $IOVA
Nuvectis: NXP200 in BRAF V600 gliomas · $NVCT
2026-10-26 — In the Chinese Phase 1b, response was 40.0% among 20 patients with high-grade glioma and 42.9% among seven with low-grade glioma. Complete responses were reported, including one still preliminary in the high-grade group. These are small cohorts without a randomized comparison.
MacroGenics: lorigerlimab in the clear-cell cohort · $MGNX
2026-10-26 — The interim LINNET analysis showed four confirmed responses among 16 evaluable patients with clear-cell gynecologic cancers: 25%. Disease control was 44%. Phase 2 continues with dose optimization; an update is expected in the first half of 2027. Estimates remain preliminary.
Eikon: updated response durability for EIK1001 · $EIKN
2026-10-26 — In the squamous cohort of TeLuRide-005, EIK1001 plus pembrolizumab and chemotherapy showed a 72% response rate and median response duration of 12.9 months. This is an open-label Phase 2 without a concurrent control. Phase 2/3 TeLuRide-008 is enrolling, with an interim dose-selection analysis expected in the second half of 2027.
Incyte: KRAS G12D and a bispecific in gastrointestinal cancers · $INCY
2026-10-26 — New combination data for INCB161734 and findings for INCA33890 support development in pancreatic and colorectal cancers. The company links early observations to DAWN-303 and NEXERA-303 and a colorectal Phase 3 planned for 2027. Collaborations for additional pancreatic-cancer combinations were also announced.
Release / document 1 · Hub $INCY
Genmab: petosemtamab plus pembrolizumab in head and neck cancer · $GMAB
2026-10-26 — The Phase 2 update reports median survival beyond two years in first-line recurrent/metastatic PD-L1-positive disease. The combination remains in development; without a randomized control in the same study, comparisons with other regimens remain indirect.
Oncolytics: response duration in anal cancer · $ONCY
2026-10-27 — Median response duration in GOBLET Cohort 4 was approximately 15 months. The proposed comparison with retifanlimab monotherapy uses historical data, not a head-to-head trial. Pelareorep’s next registrational steps and potential expansion into other HPV-associated cancers remain to be defined.
Release / document 1 · Hub $ONCY
Immunome: symptoms and physical function with varegacestat · $IMNM
2026-10-26 — Exploratory ESMO analyses add patient-reported outcomes through Week 48 to the RINGSIDE evidence in desmoid tumors. Symptom burden and physical function improved relative to placebo. The presentation expands on previously reported Phase 3 results.
TuHURA: partial responses in the first three patients · $HURA
2026-10-26 — IFx-2.0 added to pembrolizumab produced partial responses in the first three patients with metastatic Merkel cell carcinoma, all ongoing at six months. This open-label Phase 1b/2a initially plans nine patients: the finding is an early combination signal.
Aptevo: ten patients proceed to transplantation · $APVO
2026-10-26 — Ten of 47 evaluable frontline AML patients treated with mipletamig, venetoclax and azacitidine proceeded to allogeneic transplantation. Observations combine two studies; comparison with VIALE-A is historical. RAINIER dose optimization remains expected to conclude by year-end 2026.
Can-Fite: namodenoson safety and exploratory analyses · $CANF
2026-10-26 — The open-label Phase IIa in 20 pancreatic-cancer patients met its primary safety endpoint. The third-line survival subgroup includes only patients who survived beyond two months. This selection and the lack of a control prevent the signal from establishing a survival benefit.
Release / document 1 · Hub $CANF
TransCode: TTX-MC138 Phase 1a safety · $RNAZ
2026-10-26 — The ESMO poster describes safety, pharmacokinetics and disease control with TTX-MC138 in advanced solid tumors. The primary safety endpoint was met with no dose-limiting toxicity observed. Biomarkers and antitumor activity remain exploratory in a heterogeneous population.
Anixa: fifth CAR-T cohort completes dosing · $ANIX
2026-10-26 — The Phase 1 study in recurrent ovarian cancer completed fifth-cohort dosing. One patient had stable disease at 90 days; a sixth cohort is planned after the routine safety review. This is a dose-escalation update without a new comparative efficacy result.
Xilio: first patient dosed with XTX501 · $XLO
2026-10-26 — Dosing began in the Phase 1/2 XTX501 study, evaluating a PD-1/masked IL-2 bispecific in metastatic lung cancer after anti-PD-(L)1 therapy. Initial Phase 1 data are expected in the fourth quarter of 2027. Trial initiation is separate from evidence of efficacy.
Cellectar: a complete response beyond eight years · $CLRB
2026-10-27 — The report concerns one heavily pretreated DLBCL patient with a prolonged complete response after iopofosine I 131. This is an individual case the company plans to publish or present: duration is notable, while frequency and reproducibility require larger series.
CEL-SCI: a biomarker analysis of Multikine · $CVM
2026-10-26 — The company presented an analysis of its earlier Phase 3 in a population selected by nodal status and PD-L1, with five-year survival of 73.4% versus 45.0%. The finding belongs to the selected subgroup; the planned registration study must test its value prospectively.
Iambic: an IAM1363 update in HER2-driven tumors · $IAM
2026-10-26 — The October 26 release describes Phase 1/1b data presented on October 23: durable activity and intracranial responses in patients previously treated with HER2 therapies. The drug remains investigational. The presentation predates the Radar window, while the company release falls on October 26.
Immunology, rare diseases and genetic medicines
Fate: renal responses with FT819, still in a small sample · $FATE
2026-10-26 — Preliminary Phase 1 lupus-nephritis findings concern FT819 with less-intensive bendamustine conditioning. Renal responses were observed among patients evaluable at six months, supporting RECLAIM-LN. The small denominator and uncontrolled design limit efficacy conclusions.
Release / document 1 · Hub $FATE
Cullinan: trial clearances in autoimmune cytopenias · $CGEM
2026-10-27 — U.S. and Australian clearances support a Phase 1b/2a velinotamig study in relapsing/refractory ITP and warm autoimmune hemolytic anemia. The BCMA×CD3 bispecific will be evaluated with a short subcutaneous course. The clearances concern trial initiation.
Release / document 1 · Hub $CGEM
Akebia: the VOICE benefit is driven by hospitalization · $AKBA
2026-10-26 — VOICE enrolled 2,116 hemodialysis patients and compared three-times-weekly vadadustat with ESA. The hierarchical mortality/hospitalization composite favored vadadustat; hospitalizations were 10% lower, while mortality did not differ. The studied schedule is separate from authorized daily dosing.
Release / document 1 · Hub $AKBA
Eledon: quality of life after kidney transplantation · $ELDN
2026-10-26 — Phase 2 BESTOW analyses compare tegoprubart and tacrolimus on patient-reported symptom burden and quality of life at 12 months. They add the patient perspective to assessment of the immunosuppressive regimen while rejection, kidney function and safety remain essential.
Ascendis: kidney function with TransCon PTH through five years · $ASND
2026-10-26 — New follow-up and renal analyses of palopegteriparatide in hypoparathyroidism report sustained eGFR improvements. Extended analyses help assess chronic management; duration, analyzed populations and the availability of a control need to remain distinct across studies.
Biohaven: BHV-1420 and targeted autoantibody removal · $BHVN
2026-10-26 — The ASN presentation describes BHV-1420, a TRAP degrader designed to selectively remove autoantibodies associated with membranous nephropathy. The rationale and preclinical findings concern a targeted immunological strategy; patient benefit still requires clinical evidence.
Release / document 1 · Hub $BHVN
Neurogene: NGN-401 expression and central-nervous-system distribution · $NGNE
2026-10-27 — ESGCT presentations address MECP2 expression, transgene regulation and distribution after intracerebroventricular administration. The package includes in vivo/preclinical findings linked to Phase 1/2 observations in Rett syndrome. Each component needs to be read within its experimental model.
Cellectis: preclinical APOC3 editing · $CLLS
2026-10-27 — With .HEAL-101, the company reports APOC3 target editing and triglyceride reductions in mouse models. The findings belong to preclinical research presented at ESGCT and do not measure patient responses in hypertriglyceridemia.
CAMP4: EU clinical-trial authorization for CMP-002 · $CAMP
2026-10-27 — EU CTA approval permits Phase 1/2 development in SYNGAP1-related disorder, following clearances in other countries. ASCEND remains planned to begin in the fourth quarter of 2026. Clinical results for CMP-002 are still ahead.
vTv: Hybrid CATT1 begins with cadisegliatin · $VTVT
2026-10-27 — The first participant was randomized in the Phase 2a pilot in adults with type 1 diabetes using hybrid closed-loop systems. Approximately 40 participants are planned, with glycemic control including time in range assessed. This is separate from Phase 3 CATT1.
Release / document 1 · Hub $VTVT
OPKO: first participant in the acromegaly study · $OPK
2026-10-27 — OPK-8801001 enters Phase 1/2a as a long-acting growth-hormone-receptor antagonist. The program targets weekly administration; the study will first evaluate safety, tolerability, pharmacokinetics and pharmacodynamic activity.
Enanta: first patient in RESOLVE · $ENTA
2026-10-26 — The Phase 2b/3 zelicapavir study began in high-risk adults with RSV. The design is randomized and placebo-controlled; Phase 2b topline results are expected in 2027. This is operational progress, with efficacy still to be measured.
Atrium: first Corventis patient in PRKAG2 syndrome · $RNA
2026-10-27 — ATR 1072 enters a global Phase 1/2 planned for approximately 37 participants with PRKAG2-related genetic cardiomyopathy. Initial proof-of-concept data are expected in the second half of 2027. First dosing opens a trial; disease correction has yet to be demonstrated.
Equillium: first EQ504 subject and a funding milestone · $EQ
2026-10-26 — The randomized, controlled EQ504 Phase 1 began, with proof-of-mechanism data expected in the second quarter of 2027. Dosing triggers a $20 million tranche of previously announced financing. The company expects resources to support planned operations into 2029.
Solid: EU orphan designation for SGT-212 · $SLDB
2026-10-26 — The European Commission granted orphan designation in Friedreich’s ataxia. Five participants had received treatment in Phase 1b FALCON by October 5, with no related serious events reported. Initial data are expected in the first quarter of 2027. Orphan designation is separate from marketing authorization.
Earnings, revenue and financial resources
Kiniksa: ARCALYST drives revenue and guidance · $KNSA
2026-10-27 — Q3 revenue was $286.0 million, approximately 58% higher year over year; 2026 ARCALYST guidance increased to $1.045–$1.050 billion. Cash, equivalents and short-term investments were $568.8 million at September 30, with no debt. KPL-387 pivotal data remain expected in the second half of 2027.
Release / document 1 · Hub $KNSA
Wave: $431 million and RNA development on several fronts · $WVE
2026-10-27 — Cash, equivalents and securities were $431.0 million at September 30; a $12 million GSK milestone is expected in the fourth quarter. Estimated runway extends into the third quarter of 2028. WVE-006 registrational planning continues while WVE-007 advances in obesity monotherapy and combination studies.
Zura: cash and upcoming readout windows · $ZURA
2026-10-27 — Q3 net loss was $25.8 million; cash and equivalents were $187.7 million at September 30. The company estimates funding through at least the end of 2028. TibuSHIELD remains expected in the fourth quarter of 2026 and TibuSURE in the first half of 2027: projected windows, with results still ahead.
Release / document 1 · Hub $ZURA
Pharming: revenue growth, with CVID data expected in November · $PHAR
2026-10-27 — Preliminary, unaudited Q3 revenue was $117.6 million, up 21%; RUCONEST contributed $93.8 million and Joenja $23.8 million. Annual guidance narrowed to $380–$390 million. Phase 2 leniolisib results in the broader CVID population are expected in November 2026.
Novartis: operating growth and a del-desiran impairment · $NVS
2026-10-27 — Q3 revenue was $14.522 billion and core EPS $2.46. A $1.9 billion partial del-desiran impairment weighs on IFRS earnings; core operating-income guidance increased. Core measures and accounting results include different items and need to be compared separately.
Acumen: ALTITUDE-AD in November, with funding into early 2027 · $ABOS
2026-10-26 — The Q3 update points to sabirnetug topline results in early Alzheimer’s disease in November. Cash, equivalents and securities were $78.6 million at September 30, with estimated runway into early 2027. The proximity of the clinical event and funding needs makes both relevant.
Nautilus: Q3 and the ARPA-H-funded SEEDS consortium · $NAUT
2026-10-27 — Nautilus reported Q3 results and joined SEEDS to measure Alzheimer’s- and cancer-related proteoforms using Voyager. Potential funding is up to $6 million. Access to funding and platform development are separate from validation of a patient treatment.
Release / document 1 · Hub $NAUT
IQVIA: clinical-research-services growth · $IQV
2026-10-27 — Q3 revenue was $4.428 billion, up 8.0% year over year, and adjusted EPS $3.34. Net new R&D bookings reached $3.2 billion. Revenue, adjusted EBITDA and adjusted EPS guidance increased; these indicate service activity, not outcomes from customers’ trials.
Citius: higher LYMPHIR shipments, with end demand a separate measure · $CTOR, $CTXR
2026-10-26 — In the fiscal quarter ended September 30, wholesalers purchased 792 units versus 360 in the previous quarter, up 120%. Vials ordered by centers were 950 versus 926. These preliminary, unaudited figures distinguish channel shipments from patient treatment demand.
Immuron: global sales of A$2.2 million · $IMRN
2026-10-27 — In fiscal Q1 2027 ended September 30, unaudited global sales increased 9% year over year to A$2.2 million. Australian growth contrasted with lower U.S. sales, which the company partly linked to inventory and logistics. These are commercial sales, not clinical results.
SL Science: first-half results · $SLBT
2026-10-26 — Unaudited revenue for the six months ended June 30 was $1.39 million, up 23%, with a 40.2% gross margin. The comparison also reflects the commercial shift toward B2B distribution.
Novo: an October 19–23 repurchase update · $NVO
2026-10-26 — Cumulative purchases in the tranche initiated on May 6 reached 25,515,000 B shares. This updates an existing program within the overall plan of up to DKK15 billion; it is not a newly announced plan of that amount on October 26.
Research, diagnostics and scientific presentations
Co-Diagnostics: tuberculosis-test filing in India · $CODX
2026-10-27 — Joint venture CoSara completed its study and filed with CDSCO. The study includes 676 samples; among the 233 compared with MGIT, average sensitivity was 97.3% and specificity 96.0% across three lots. Authorization and launch are expected by year-end 2026: company forecasts, with clearance still pending.
Release / document 1 · Hub $CODX
Natera: Signatera Genome and MRD-guided treatment · $NTRA
2026-10-27 — The ESMO presentation concerns molecular residual-disease detection in bladder cancer using phased and structural variants. The test’s clinical application needs to be assessed alongside trial design and the treatment strategy informed by its result.
Natera: real-world Renasight analyses in nephrology · $NTRA
2026-10-26 — ASN analyses examine the contribution of Renasight genetic testing in kidney disease. These are diagnostic and observational findings, distinct from drug-efficacy data.
Madrigal: Rezdiffra at The Liver Meeting · $MDGL
2026-10-27 — Clinical and real-world-evidence abstracts were announced for the November 5–9 meeting. The largest dataset includes more than 12,000 patients; topics include effectiveness in practice, tolerability and persistence. This is a conference announcement; individual analyses require their own data assessment.
Release / document 1 · Hub $MDGL
Voyager: VY1706 and VY7523 at CTAD · $VYGR
2026-10-27 — Posters were announced on tau-targeted gene therapy VY1706 and anti-tau antibody VY7523 in Alzheimer’s disease. The release sets out the presentation program; individual results need assessment within their clinical or preclinical context.
MeiraGTx: four posters across ESGCT and NEALS · $MGTX
2026-10-27 — Three ESGCT posters and one NEALS poster cover genetic-medicine and cell-therapy platforms. Topics include technology characterization and development. Platform presentations carry different evidentiary weight from new registrational patient results.
Tonix: physical symptoms and function with TONMYA · $TNXP
2026-10-27 — An analysis of the earlier RELIEF and RESILIENT studies adds Week 14 FIQR findings in fibromyalgia. It expands on the two Phase 3 datasets supporting the already marketed medicine.
Neurocrine: measuring patient-reported improvement · $NBIX
2026-10-26 — A new analysis proposes a six-point EQ-VAS increase as a clinically meaningful change threshold in tardive dyskinesia treated with valbenazine. It helps interpret perceived health alongside disorder-specific measures.
Artelo: ART26.12 at IASP · $ARTL
2026-10-26 — An October 29 presentation was announced on nonclinical and single-dose Phase 1 findings for the FABP5 inhibitor. The company is preparing a multiple-dose study in the fourth quarter; the release does not present a new controlled patient-efficacy result.
Release / document 1 · Hub $ARTL
BioVie: bezisterim at the RECOVER-TLC workshop · $BIVI
2026-10-26 — A November 5 presentation was announced on Phase 2 ADDRESS-LC findings in neurological Long COVID symptoms. The workshop invitation provides scientific discussion, with regulatory validation of the treatment a separate question.
Propanc: cell-model findings in chemotherapy resistance · $PPCB
2026-10-26 — PRP showed activity in preclinical models of chemotherapy-resistant pancreatic-cancer cells. The observations concern cell-state modulation and sensitization, not patient outcomes. First-in-human testing is planned for the first quarter of 2027.
Calidi: CLD-401 and the in situ TCE platform · $CLDI
2026-10-27 — The release summarizes ESMO presentations on CLD-401 and RedTail, designed to generate T-cell engagers locally within tumors. Platform and preclinical findings describe a development rationale without establishing clinical benefit.
Clearmind: first AUD cohort recruitment completed · $CMND
2026-10-27 — CMND-100 completed recruitment for the first segment of its evaluation in patients with alcohol-use disorder. Phase I/IIa focuses on safety, tolerability and pharmacokinetics, with early exploratory efficacy signals.
Polyrizon: 120 NASARIX participants · $PLRZ
2026-10-27 — Enrollment and randomization were completed at five U.S. sites in the controlled nasal-hydrogel study for allergic rhinitis. The comparator is saline. Enrollment completion precedes the results readout.
60 Degrees: five patients complete expanded-access treatment · $SXTP
2026-10-27 — In relapsing babesiosis, all five patients who completed tafenoquine-containing regimens reported improvement and negative conventional PCR. Four of five were also negative on the more sensitive NAT assay. This is a small, uncontrolled series, separate from Phase 3 evidence.
NanoViricides: an NV-387 development update · $NNVC
2026-10-27 — The company updated its NV-387 antiviral program and oral formulation. Potential Ebola applications cited in the release require disease-specific clinical data; promotional communication about the program does not demonstrate benefit in Ebola patients.
Release / document 1 · Hub $NNVC
NeOnc: proposed international trial expansion · $NTHI
2026-10-26 — The release outlines a proposed brain-cancer program targeting approximately 500 patients, 30 hospitals and three countries. These are project objectives; they do not establish that all sites are active or patients enrolled.
Daré: the programmable DARE-IDDS device · $DARE
2026-10-26 — The October 30 PODD presentation will cover an investigational programmable subcutaneous device for repeated dosing and wireless control. These are drug-delivery design features, with development and validation still required.
GT Biopharma: a KRAS/NK combination at SITC · $GTBP
2026-10-26 — A November 6 oral presentation was announced on sensitizing pancreatic cancer to NK immunotherapy through KRAS inhibition. The release concerns conference selection and the research rationale.
Cerenome: a ReSPECT-LM update at SNO · $CNSY
2026-10-27 — An interim clinical-data poster on multiple REYOBIQ doses in leptomeningeal metastases and a symposium were announced for SNO on November 12–15. The presentation schedule precedes full assessment of the new data.
Immuneering: the Phase 3 MAPKeeper 301 design · $IMRX
2026-10-26 — The October 26 release summarizes the October 25 ESMO poster on the ongoing registrational trial’s methodology. It describes the atebimetinib pancreatic-cancer study design; Phase 3 results remain a future milestone.
Release / document 1 · Hub $IMRX
Niki: APOE authorization extended to additional sample types · $NIKI
2026-10-26 — The October 26 announcement concerns an October 23 authorization extending approved APOE-genotyping sample types to dried blood spots, plasma and urine. The test’s earlier authorization dates to 2025. Sample authorization is separate from an Alzheimer’s diagnosis or treatment approval.
Deals, financing and corporate developments
Regeneron: approximately $270 million for additional Inmazeb supply · $REGN
2026-10-26 — The BARDA agreement was extended to supply additional Ebola-treatment doses through 2031. Expected additional value is approximately $270 million. This is a preparedness procurement agreement, separate from new efficacy findings.
Corxel: a listing agreement with Amanat · $AMAN
2026-10-26 — Corxel US and Amanat signed a definitive business-combination agreement for an oral-obesity-medicine company. The portfolio includes GLP-1 agonist CX11 and preclinical amylin agonist CX12. The proposed transaction remains subject to closing conditions.
Skye: a preliminary proxy for the Redx transaction · $SKYE
2026-10-26 — The preliminary proxy filing updates the proposed Redx combination and prospective ownership structure. Stated exchange ratios and completion remain subject to the transaction terms.
Lycia closes an approximately $365.1 million IPO · $LYCA
2026-10-26 — The expanded offering of 20,286,000 shares at $18 closed, including the underwriters’ option. Proceeds are gross. Trading began on October 23; the October 26 development is the offering’s closing.
Aclaris: a $50 million offering · $ACRS
2026-10-27 — The share and pre-funded-warrant offering was priced for expected gross proceeds of $50 million. Financing accompanies pipeline development and introduces new securities, requiring assessment alongside the resources raised.
Actuate: an $11 million offering with warrants · $ACTU
2026-10-27 — The share-and-warrant offering targets approximately $11 million in gross proceeds, with closing expected on October 28. Warrants introduce potential dilution beyond the shares sold in the offering.
GeoVax: a $1 million revolving facility · $GOVX
2026-10-27 — The update concerns the unsecured October 23 revolving-loan agreement for up to $1 million, carrying 12% annual interest and a 12-month term from issuance. Advances require lender approval; the agreement accompanies board changes. The initial announcement was issued on October 26.
Release / document 1 · Release / document 2
aTyr: a one-for-40 reverse split · $ATYR
2026-10-27 — Effectiveness is planned for October 28 at 5 p.m. ET, with adjusted trading from October 29. The objective is to regain Nasdaq minimum-bid compliance. Consolidation changes share count and unit price proportionally; by itself it creates no economic value.
Release / document 1 · Hub $ATYR
Enlivex: a delisting notice and planned appeal · $ENLV
2026-10-27 — Following Nasdaq’s minimum-bid delisting notice, the company intends to request a hearing. The release identifies a one-for-16 reverse split effective October 27. A procedural stay during an appeal does not guarantee the final outcome.
InMed: a contingent-rights record date · $INM
2026-10-26 — November 5 was set as the CVR record date for the proposed Mentari merger. Distribution remains conditional on the November 4 shareholder vote and applicable terms. The rights provide potential contingent payments, not a guaranteed amount.
Valion: preliminary interest in Velocity Bioworks · $VBIO
2026-10-26 — Unsolicited acquisition inquiries were received for the CDMO subsidiary. The company is in preliminary discussions within its strategic review; a sale has not been agreed or completed.
Pluri and ZEO: a U.S. manufacturing and commercial agreement · $PLUR
2026-10-26 — The definitive agreement links cell technology with manufacturing and distribution in regenerative medicine. The contemplated structure gives Pluri 50% ownership in ZEO at closing after the applicable steps. The industrial agreement is separate from clinical product approval.
RadNet: an ONRAD acquisition agreement · $RDNT
2026-10-26 — RadNet announced an agreement to acquire ONRAD, expanding teleradiology and professional services. The development concerns diagnostic-services infrastructure; completion remains subject to transaction conditions.
Charles River: virtual control groups in GLP studies · $CRL
2026-10-27 — The company described virtual control groups for preclinical GLP studies. This updates research services and methodology; suitability needs to be assessed for each program within the relevant regulatory context.
Satellos: a new scientific advisory board · $MSLE
2026-10-27 — A scientific advisory board was established to explore regeneration, aging, neuroscience and small-molecule chemistry. It expands long-term scientific advice, without new clinical results in the release.
Release / document 1 · Hub $MSLE
Spero: regulatory and business-development functions strengthened · $SPRO
2026-10-26 — New regulatory/quality and business-development appointments support the immunology pipeline. The chief operating officer will retire on December 31. The release concerns organization, without new efficacy data.
Release / document 1 · Hub $SPRO
Helus: cofounders transition from executive roles · $HELP
2026-10-27 — The cofounders leave executive roles while retaining board positions; an independent chair was appointed. The company reiterated expected APPROACH results in the fourth quarter of 2026. This is a governance transition ahead of the clinical event.
Release / document 1 · Hub $HELP
Altimmune: two new directors from November 2 · $ALT
2026-10-27 — The board expands from nine to eleven members through appointments approved on October 23 and effective November 2. Added expertise covers biotech management and finance.
Release / document 1 · Hub $ALT
Optimi: an Australian distribution subsidiary · $OPTH
2026-10-26 — A subsidiary was established for distribution and business development of regulated psychedelic products in Australia. The expansion concerns the commercial network within the local authorization framework.
Estrella: an executive transition and scientific continuity · $ESLA
2026-10-26 — A new chief executive and board chair was appointed; the previous CEO becomes chief scientific officer. Effective October 25, the transition concerns the leadership structure.
Adial: a planned finance-leadership appointment · $ADIL
2026-10-26 — A planned chief financial officer appointment was announced. This is a management update, separate from clinical readouts in the alcohol-use-disorder program.
Aurora: Curaleaf’s ATM challenge dismissed · $ACB
2026-10-26 — Aurora reported that the Alberta Securities Commission dismissed the application against its ATM program. The company reiterated that it had not used the program during the hostile bid. The financing-program decision and the Curaleaf corporate contest are distinct.
Release / document 1 · Hub $ACB
Canopy: shareholder-meeting results · $CGC
2026-10-26 — Shareholders approved the matters submitted at the meeting reconvened on October 23. The October 26 announcement concerns voting outcomes and governance, without a new clinical result.
Release / document 1 · Hub $CGC
Lilly/Novo: request to block advertisements denied · $LLY, $NVO
2026-10-26 — The New Jersey federal court denied Novo Nordisk’s request for a preliminary injunction against Lilly’s weight-loss-drug advertisements. This permits the challenged campaigns to continue; it is not a final decision on every issue in the lawsuit.
Release / document 1 · Hub $NVO
Medicus: Nasdaq minimum-bid compliance regained · $MDCX
2026-10-26 — The company reported regaining minimum-bid-price compliance. This updates listing status; pipeline progress remains a separate matter.
Onconetix: a reverse split announced · $ONCO
2026-10-26 — A one-for-ten reverse split was announced, with effectiveness expected on November 6. Authorized shares remain unchanged while outstanding shares decrease proportionally. This updates capitalization and listing.
Agenda: events announced on October 26–27
Other corporate notices
Informational and educational content prepared with AI assistance and checked against the linked sources. Interpretations are blog commentary; company objectives, clinical windows and cash-runway estimates remain forecasts. This is not financial advice or an investment recommendation. Conduct independent research and consult a licensed adviser before making investment decisions.
